Fecal microbiota transplantation in gastrointestinal diseases: what practicing physicians should know.

Borody, TJ; Connelly, N; Mitchell, SW

Fecal microbiota transplantation in gastrointestinal diseases: what practicing physicians should know.

Borody, TJ Connelly, N Mitchell, SW

Permalink

Publication Type:: Journal Article
Citation:: Pol Arch Med Wewn, 2015, 125 (11), pp. 852 - 858
Issue Date:: 2015

Closed Access

	Filename	Description	Size
	inv_rev_Borody_ONLINE.pdf	Accepted Manuscript Version	160.45 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Borody, TJ	en_US
dc.contributor.author	Connelly, N	en_US
dc.contributor.author	Mitchell, SW	en_US
dc.date.issued	2015	en_US
dc.identifier.citation	Pol Arch Med Wewn, 2015, 125 (11), pp. 852 - 858	en_US
dc.identifier.uri	http://hdl.handle.net/10453/41588
dc.description.abstract	Clostridium difficile infection (CDI) is one of the most commonly reported nosocomial pathogens in the United States and Europe, with recent CDI-associated mortality in the United States approaching 30 000 deaths annually. Antibiotics remain the preferred treatment for CDI; however, a minority of patients experience numerous relapses and are treated with restoration of the bowel microbiota, termed fecal microbiota transplantation (FMT). FMT involves the introduction of a fecal suspension from a healthy donor into the gut of the infected patient to cure the CDI and replace depleted components of the gut microbiota. FMT is particularly effective and safe in curing CDI, using a colonoscope or enema to deliver 1 to 2 infusions. Given that 6425 CDIs were reported in Poland in 2014, practicing physicians should understand the benefits and limitations of FMT in CDI as this novel therapy has rapidly advanced to the level of the "standard-of-care" status in Australia, the United States, and many parts of Europe. FMT has been administered either as a suspension in saline, a highly refined liquid product which can be frozen, as lyophilized powder in capsules, and as an encapsulated spore preparation. The ultimate products to reach the market will be shaped by the indications approved by regulatory bodies. At present, the fecal suspension in saline remains the treatment of choice to terminate relapsing and severe CDI, which we will review here. The use of FMT for non-CDI indications, such as inflammatory bowel disease and irritable bowel syndrome, is likely to increase. At present, these indications remain in the domain of research institutions.	en_US
dc.language	eng	en_US
dc.relation.ispartof	Pol Arch Med Wewn	en_US
dc.relation.isbasedon	10.20452/pamw.3166	en_US
dc.subject.classification	Cardiovascular System & Hematology	en_US
dc.subject.mesh	Feces	en_US
dc.subject.mesh	Humans	en_US
dc.subject.mesh	Clostridium Infections	en_US
dc.subject.mesh	Gastrointestinal Diseases	en_US
dc.subject.mesh	Biological Therapy	en_US
dc.subject.mesh	Developed Countries	en_US
dc.subject.mesh	Clinical Competence	en_US
dc.subject.mesh	Disease Management	en_US
dc.subject.mesh	Poland	en_US
dc.subject.mesh	Gastrointestinal Microbiome	en_US
dc.subject.mesh	Fecal Microbiota Transplantation	en_US
dc.title	Fecal microbiota transplantation in gastrointestinal diseases: what practicing physicians should know.	en_US
dc.type	Journal Article
utslib.citation.volume	11	en_US
utslib.citation.volume	125	en_US
utslib.location.activity	Poland	en_US
utslib.for	1102 Cardiorespiratory Medicine and Haematology	en_US
utslib.for	1103 Clinical Sciences	en_US
utslib.for	1117 Public Health and Health Services	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
utslib.copyright.status	closed_access
pubs.issue	11	en_US
pubs.publication-status	Published	en_US
pubs.volume	125	en_US

Abstract:

Clostridium difficile infection (CDI) is one of the most commonly reported nosocomial pathogens in the United States and Europe, with recent CDI-associated mortality in the United States approaching 30 000 deaths annually. Antibiotics remain the preferred treatment for CDI; however, a minority of patients experience numerous relapses and are treated with restoration of the bowel microbiota, termed fecal microbiota transplantation (FMT). FMT involves the introduction of a fecal suspension from a healthy donor into the gut of the infected patient to cure the CDI and replace depleted components of the gut microbiota. FMT is particularly effective and safe in curing CDI, using a colonoscope or enema to deliver 1 to 2 infusions. Given that 6425 CDIs were reported in Poland in 2014, practicing physicians should understand the benefits and limitations of FMT in CDI as this novel therapy has rapidly advanced to the level of the "standard-of-care" status in Australia, the United States, and many parts of Europe. FMT has been administered either as a suspension in saline, a highly refined liquid product which can be frozen, as lyophilized powder in capsules, and as an encapsulated spore preparation. The ultimate products to reach the market will be shaped by the indications approved by regulatory bodies. At present, the fecal suspension in saline remains the treatment of choice to terminate relapsing and severe CDI, which we will review here. The use of FMT for non-CDI indications, such as inflammatory bowel disease and irritable bowel syndrome, is likely to increase. At present, these indications remain in the domain of research institutions.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/41588